Becoming the largest AI-powered Drug Assets Manager
We Dare to Care
OUR CAPABILITIES
DATA
World’s Largest Data Ocean
of Public and Proprietary Data
326M+
Web
Domains
50k+
Sources
Updated Daily
1M+
Clinical Trials &
Preclinical Studies
40M+
Biomedical
Terms & Concepts
1.5M+
Patients
Records
Decision Making
Answering the most important questions in developing treatment for incurable diseases
Artificial Intelligence
AI-Enabled Novel
Hypotheses Across LS
Value Chain
Hypotheses Across LS
Value Chain
Successfully
Used by 50+
Organisations
Used by 50+
Organisations
Up to 50%
Time-Saving in
Drug Discovery
Time-Saving in
Drug Discovery
65+ Patents,
125+ Patents
Filed
125+ Patents
Filed
In-Vitro Validation
High Throughput
Screening Capabilities
Screening Capabilities
Biophysical
Characterization
Characterization
Medicinal Chemistry and
de-novo Molecule Manufacturing
de-novo Molecule Manufacturing
DRUG ASSETS
A Portfolio of Partnered &
In-House Assets
30 Drug Discovery
Partnerships
Partnerships
Our latest News
Partex & Singapore’s EDDC collaborate to bring forward an innovative approach for early drug discovery & development
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation
Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development
AIO-Studien-gGmbH and Amrit – a Partex Company are jointly announcing the start of a pilot project as part of the AIO data hub initiative
Parexel and Partex announce innovative partnership leveraging AI & big data to accelerate drug discovery & development